ribavirin / Generic mfg. - LARVOL DELTA

UMIT-1, Phase IB Trial: IV favipiravir and ribavirin for the treatment of CCHF (ESCMID Global 2026) - No abstract available

Late-breaking abstract • P1 data

Reassessing ribavirin in Lassa fever therapy: clinical impact of the modified McCormick (salvage) regimen in a Nigerian cohort (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Experimental hepatitis E virus genotype 1 infection in three types of wild rodents. (PubMed, PLoS Pathog) - "Re-inoculation experiments confirmed infection-induced protective immunity, and ribavirin treatment effectively suppressed viral replication. HEV-1 infection can be established by oral gavage inoculation, close contact and vertical transmission. These results provide solid evidence that wild rodents can serve as potential hosts for HEV-1, highlighting the potential role of wild rodents in HEV-1 ecology and cross-species transmission."

Journal • Preclinical • Infectious Disease • Inflammation • IL18 • IL1B

Zinc acetate enhances glucose-regulated protein 78 and anti-HAV activity of ribavirin in vitro (APASL 2026) - No abstract available

Preclinical

Treatment outcome of interferon based therapy versus sofosbuvir ribavirin therapy in chronic hepatitis C genotype 3 and compensated liver cirrhosis (APASL 2026) - No abstract available

Clinical • Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

PRE-EXISTING ANEMIA INVERSELY RELATED TO RIBAVIRIN INDUCED ANEMIA IN CIRRHOTIC PATIENTS WITH VIRAL HEPATITIS C INFECTION (APASL 2026) - No abstract available

Clinical • Anemia • Hematological Disorders • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis

A mouse-adapted Yezo virus model for antiviral testing in immunocompetent mice. (PubMed, Nat Commun) - "Ribavirin treatment effectively suppressed viral replication, prevented mortality, and mitigated tissue damage, whereas remdesivir showed no efficacy. This model provides a critical tool for studying YEZV pathogenesis and antiviral development, while the identified mutations offer insights into viral adaptation and virulence mechanisms. Our findings underscore the potential of MA-YEZV as a platform for evaluating countermeasures against emerging orthonairoviruses."

Journal • Preclinical • Hematological Disorders • Hepatology • Infectious Disease • Inflammation • Leukopenia • Liver Failure • Thrombocytopenia • IFNG • IL6 • TNFA

Synthesis, antiviral activity and mechanistic insights into cytidine derivatives. (PubMed, Pest Manag Sci) - "Structure-activity relationships (SARs) were established for the cytidine derivatives, providing guidance for the design of cytidine-based antiviral agents. Given its potent antiviral activity and unique mechanism of action, 5z shows strong promise as a novel antiviral agent."

Journal

ORF1-driven ribavirin treatment failure in chronic hepatitis E virus infection revealed by integrated patient and in vitro analyses (EASL 2026) - No abstract available

Preclinical • Hepatology • Infectious Disease • Inflammation

Do's and Don'ts in liver transplantation for viral hepatitis: From B to E (EASL 2026) - "This session will provide an evidence-based and practice-oriented update on the management of viral hepatitis (HBV, HDV, HCV, HEV) in the liver transplant setting, from listing to long-term follow-up, highlighting best practices and common pitfalls. Learning objectives: When to initiate antiviral therapy in listed patientsPredicting and achieving delisting: from DAA to finite HBV controlTolerance and timing: when "too late" or "too early" mattersUse of new HDV therapies during the waiting list periodIdentifying chronic HEV infection under immunosuppressionWhen to reduce immunosuppression vs. start antiviralsDuration, relapse risk and prevention strategiesHow to manage HEV infection when ribavirin therapy fails: alternative strategies and follow-upHBIG-free and finite-HBIG strategies: what works and for whomDo new antivirals for HDV change our HBV prophylaxis strategy?Do evolving HCC treatments after LT reshape our approach to viral control?Avoiding..."

Hepatology • Infectious Disease • Inflammation • Transplantation

A New Paradigm for RSV Treatment: EV148 Leverages Pre-Existing Immunity to Achieve Strain-Independent Antiviral Efficacy in Neonatal Lambs (RSVVW 2026) - "Monoclonal antibodies such as palivizumab and nirsevimab provide prophylaxis for high-risk populations but demonstrate limited therapeutic efficacy in hospitalized patients with established infection...In therapeutic BALB/c mouse models, single-dose subcutaneous treatment 72 hours post-infection reduced nasal viral titers by >4.0 log₁₀ and viral RNA by >3.0 log₁₀—outperforming ribavirin, Presatovir, and investigational fusion inhibitors...Most critically, in blinded neonatal lamb studies—a translationally relevant large animal model that recapitulates human infant lower respiratory tract disease—single-dose EV148 administered 24 hours post-infection reduced gross lung lesions by 75%, significantly decreased viral titers in both lung tissue and bronchoalveolar lavage fluid with dose-dependent reductions in viral RNA, and prevented clinical disease progression including abnormal lung sounds and elevated resting respiratory rates. These data establish EV148 as a..."

Clinical • IO biomarker • Infectious Disease • Inflammation • Influenza • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG • IL1B • IL6 • TNFA

A New Paradigm for RSV Treatment: EV148 Leverages Pre-Existing Immunity to Achieve Strain-Independent Antiviral Efficacy in Neonatal Lambs. (RSVVW 2026) - "Monoclonal antibodies such as palivizumab and nirsevimab provide prophylaxis for high-risk populations but demonstrate limited therapeutic efficacy in hospitalized patients with established infection...In therapeutic BALB/c mouse models, single-dose subcutaneous treatment 72 hours post-infection reduced nasal viral titers by >4.0 log₁₀ and viral RNA by >3.0 log₁₀—outperforming ribavirin, Presatovir, and investigational fusion inhibitors...Most critically, in blinded neonatal lamb studies—a translationally relevant large animal model that recapitulates human infant lower respiratory tract disease—single-dose EV148 administered 24 hours post-infection reduced gross lung lesions by 75%, significantly decreased viral titers in both lung tissue and bronchoalveolar lavage fluid with dose-dependent reductions in viral RNA, and prevented clinical disease progression including abnormal lung sounds and elevated resting respiratory rates. These data establish EV148 as a..."

Clinical • IO biomarker • Infectious Disease • Inflammation • Influenza • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG • IL1B • IL6 • TNFA

Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis. (PubMed, Front Gastroenterol (Lausanne)) - "However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilaprevir (VOX), and glecaprevir (GLE) + pibrentasvir (PIB) in treating patients infected with HCV GT3 in a real-world setting. SOF+VEL ± RBV, GLE+PIB, and SOF+VEL+VOX had good antiviral effectiveness for chronic HCV-GT3 infection in real-world settings. Factors such as cirrhosis and treatment experience, especially previous DAA treatment failure, may influence the SVR rate."

Journal • Real-world evidence • Retrospective data • Review • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

ASTROVIRUS ENCEPHALITIS STATUS POST STEM CELL TRANSPLANT (EBMT 2026) - "Preparative regimen was TBI (1200 cGY), cyclophosphamide, thiotepa, and distal rabbit ATG without GVHD prophylaxis...Therapies included empiric cidofovir for adenovirus viremia, and therapeutic plasma exchange (TPE) for a possible immune-mediated process...mNGS of CSF subsequently identified human astrovirus VA1, establishing the diagnosis.Antiviral treatments included: administrations of high-dose IVIG, ribavirin, nitazoxanide and remdesivir... Astrovirus encephalitis is a rare but important cause of neurologic decline after HSCT, particularly in patients with T-cell dysfunction. Diagnosis often requires mNGS, as routine CSF testing may be negative. Early consideration of atypical neurotropic viruses is essential when evaluating unexplained encephalopathy in post-transplant patients due to the high morbidity and mortality."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • CNS Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation • KMT2A

Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models. (PubMed, Gut) - "Given BEM's favourable safety profile in preclinical and clinical settings, our results suggest investigating its efficacy in patients with chronic HEV infection."

Journal • Preclinical • Hepatology • Infectious Disease • Inflammation

IMPACT OF HEPATITIS E VIRUS INFECTION ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CURRENT TREATMENT STATUS (EBMT 2026) - "Two patients received ribavirin with or without interferon therapy, while two did not... Hepatitis E virus infection is not exclusively hepatotropic and can involve multiple organ systems. Time to viral clearance is prolonged in allo-HSCT patients, and HEV may exert a non-negligibie impact on transplantation outcomes. Further studies with larger sample sizes are warranted to clarify its clinical significance and optimize management strategies."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Cerebral Hemorrhage • Chronic Graft versus Host Disease • CNS Disorders • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Pneumonia • Respiratory Diseases • Transplantation

MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY (EBMT 2026) - "All patients received myeloablative conditioning, including total body irradiation–based regimens (n=13) or busulfan/treosulfan-based regimens (n=3); one patient received thiotepa, fludarabine, and cyclophosphamide. Cyclosporine, ATG, and ATLG were administered in 9, 4, and 6 patients, respectively; ex vivo and in vivo T-cell depletion was performed in 6 and 1 patients.HCV genotypes were 1 (n=7) and 2 (n=8). Five patients received pre-HCT treatment with lamivudine (n=2), ledipasvir/sofosbuvir(n=2), and ribavirin (n=1), while 9 patients were treated after HCT with sofosbuvir (n=2), ledipasvir/sofosbuvir (n=3), glecaprevir/pibrentasvir (n=3), and sofosbuvir/velpatasvir (n=1); three were never treated... Our data suggest that HCT can be safely performed in pediatric patients with active HCV infection, even in the setting of intensive immunosuppression including in vivo and ex vivo T-cell depletion. Pre-transplant HCV viral load and DAAs exposure did not negatively impact..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Leukemia • Pediatrics • Transplantation • Transplantation Associated Thrombotic Microangiopathy

COMPARATIVE STUDY OF RESPIRATORY SYNCYTIAL VIRUS BURDEN AND TREATMENT POLICIES IN HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS (EBMT 2026) - "Treatment practices varied, with ribavirin ± IVIG used exclusively at Erasmus MC (51% of cases)... RSV infection was infrequent and associated with relatively low morbidity and mortality across geographically and economically diverse HCT centres. Universal pre-transplant RSV prophylaxis appears unnecessary; however, targeted preventive strategies may benefit patients at highest risk. These findings provide a contemporary benchmark for developing harmonised RSV management pathways in HCT recipients."

Clinical • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation

Design and Multi-Level Biological Evaluation of Naphthyridine-Based Derivatives as Topoisomerase I/II-Targeted Anticancer Agents with Anti-Fowlpox Virus Activity Supported by In Silico Analysis. (PubMed, Int J Mol Sci) - "Compound 5b showed the highest activity against HeLa cells, compound 1 was most effective against HCT-116 cells, while compounds 7 and 8 displayed remarkable activity against MCF-7 cells, with compound 7 surpassing doxorubicin and compound 8 demonstrating excellent selectivity toward normal cells...Selected derivatives were further evaluated for antiviral activity against fowlpox virus using in ovo and in vivo SPF embryonated chicken egg models, where compounds 2 and 9a exhibited the highest therapeutic indices, comparable to ribavirin, and compound 9a markedly suppressed viral replication and titers in vivo. ADMET profiling, molecular docking, molecular dynamics simulations, and DFT calculations supported the experimental findings and identified compound 10a as the most favorable theoretical candidate. Overall, this integrated experimental-computational approach establishes naphthyridine derivatives as a rationally designed multifunctional chemotype for simultaneous..."

Journal • Oncology • CASP9 • TOP1

COMPARATIVE STUDY OF RESPIRATORY SYNCYTIAL VIRUS BURDEN AND TREATMENT POLICIES IN HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS (EBMT 2026) - "Treatment practices varied, with ribavirin ± IVIG used exclusively at Erasmus MC (51% of cases)... RSV infection was infrequent and associated with relatively low morbidity and mortality across geographically and economically diverse HCT centres. Universal pre-transplant RSV prophylaxis appears unnecessary; however, targeted preventive strategies may benefit patients at highest risk. These findings provide a contemporary benchmark for developing harmonised RSV management pathways in HCT recipients."

Clinical • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation

MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY (EBMT 2026) - "All patients received myeloablative conditioning, including total body irradiation–based regimens (n=13) or busulfan/treosulfan-based regimens (n=3); one patient received thiotepa, fludarabine, and cyclophosphamide. Cyclosporine, ATG, and ATLG were administered in 9, 4, and 6 patients, respectively; ex vivo and in vivo T-cell depletion was performed in 6 and 1 patients.HCV genotypes were 1 (n=7) and 2 (n=8). Five patients received pre-HCT treatment with lamivudine (n=2), ledipasvir/sofosbuvir(n=2), and ribavirin (n=1), while 9 patients were treated after HCT with sofosbuvir (n=2), ledipasvir/sofosbuvir (n=3), glecaprevir/pibrentasvir (n=3), and sofosbuvir/velpatasvir (n=1); three were never treated... Our data suggest that HCT can be safely performed in pediatric patients with active HCV infection, even in the setting of intensive immunosuppression including in vivo and ex vivo T-cell depletion. Pre-transplant HCV viral load and DAAs exposure did not negatively impact..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Leukemia • Pediatrics • Transplantation • Transplantation Associated Thrombotic Microangiopathy

COMBINATION ANTIVIRAL TREATMENT IS EFFECTIVE IN TREATING PARAINFLUENZA 3INFECTION IN THE IMMEDIATE POST-TRANSPLANT SETTING, INCLUDING IN PATIENTS WITH IN-VIVO T-CELL DEPLETION (EBMT 2026) - " Case 1: A 9-month-old male received a Fludarabine(160mg/m2)/Treosulfan(36g/m2)/Thiotepa(10mg/kg) (FTT)-Alemtuzumab (1g/kg) conditioned 12/12 HLA-Matched Unrelated Donor Bone Marrow HSCT for high-risk Infant Acute Lymphoblastic Leukaemia...She was treated with IVIg (D+14), Ribavirin(D+14), and Remdesivir(D+15), with rapid complete resolution of symptoms, and rapid rise (i.e. decrease in viral load) in Parainfluenza Ct values on throat swabs.Case 3: A 15-year-old female with severe aplastic anaemia and fungal pneumonia was admitted for a Fludarabine(150mg/m2)/Cyclophosphamide(120mg/kg)-Alemtuzumab (0.3mg/kg) conditioned 12/12 HLA-Matched Sibling Bone Marrow HSCT...There were liver function test derangements in Case 1 (Bilirubin 46μmol/L, ALT 3x upper limit of normal (ULN), AST 5xULN) requiring dose interruption of Nitazoxanide/Favipiravir, but this was in the context of significant deterioration in clinical condition... Combination therapy with Ribavirin, Remdesivir,..."

Post-transplantation • Preclinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Otorhinolaryngology • Pneumonia • Respiratory Diseases • T Acute Lymphoblastic Leukemia • Transplantation

IMPACT OF HEPATITIS E VIRUS INFECTION ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CURRENT TREATMENT STATUS (EBMT 2026) - "Two patients received ribavirin with or without interferon therapy, while two did not... Hepatitis E virus infection is not exclusively hepatotropic and can involve multiple organ systems. Time to viral clearance is prolonged in allo-HSCT patients, and HEV may exert a non-negligibie impact on transplantation outcomes. Further studies with larger sample sizes are warranted to clarify its clinical significance and optimize management strategies."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Cerebral Hemorrhage • Chronic Graft versus Host Disease • CNS Disorders • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Pneumonia • Respiratory Diseases • Transplantation

Chronic persistent Norovirus in the immune-compromised host. (PubMed, Curr Opin Infect Dis) - "Chronic norovirus infection in immunocompromised individuals remains an under-recognized and difficult-to-treat condition. Future progress requires development of evidence-based antiviral therapies, and effective vaccines to mitigate long-term morbidity."

Journal • Review • Bone Marrow Transplantation • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Primary Immunodeficiency • Solid Organ Transplantation • Transplantation

Our Experience with Combination Therapy and it's Outcomes in Pediatric Subacute Sclerosing Panencephalitis: A Retrospective Case Series (AAN 2026) - "All of them received monthly doses of intrathecal interferon alpha-2B (1.2 million IU), along with daily oral ribavirin (15 mg/kg), isoprinosine (50 mg/kg), and levamisole (2.5 mg/kg). Combination therapy offered only transient benefit and failed to alter the trajectory of the disease. Our findings highlight the urgency of early diagnosis and reinforce the fact that measles vaccination is the only effective preventive strategy against SSPE."

Combination therapy • Retrospective data • CNS Disorders • Infectious Disease • Measles • Movement Disorders • Pediatrics • Pneumonia • Respiratory Diseases • Septic Shock